NCT06096974View on ClinicalTrials.gov

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

YL-17231

YL-17231 will be administered orally once daily in a continuous regimen

Trial Locations (3)

45219

RECRUITING

The Lindner Center for Research & Education at The Christ Hospital, Cincinnati

77030

RECRUITING

MD Anderson Cancer Center, Houston

84112

RECRUITING

Huntsman Cancer Institute and Hospital, University of Utah, Salt Lake City

All Listed Sponsors
lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY